Venaxis, Inc. (APPY)
-NasdaqCM 1.97 
0.05(2.48%) 4:00PM EDT
| Prev Close: | 2.02 |
|---|
| Open: | 1.99 |
|---|
| Bid: | N/A |
|---|
| Ask: | 2.42 x 300 |
|---|
| 1y Target Est: | 5.25 |
|---|
| Beta: | 0.63 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.96 - 2.09 |
|---|
| 52wk Range: | 1.15 - 3.17 |
|---|
| Volume: | 721,560 |
|---|
| Avg Vol (3m): | 876,738 |
|---|
| Market Cap: | 42.26M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.06 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, Sep 26)
- Venaxis' APPY1™ Test Passes Final Futility Analysis in Pivotal Clinical StudyPR Newswire(Thu, Sep 26)
- Venaxis Is Getting Ready To Take Off, All On Board?at Seeking Alpha(Sun, Sep 8)
- 4 Biotech Stocks Under $10 on the Verge of Breakoutsat TheStreet(Thu, Sep 5)
- Venaxis to Present at Three Upcoming Investor ConferencesPR Newswire(Thu, Sep 5)
- VENAXIS, INC. FinancialsEDGAR Online Financials(Tue, Aug 20)
- Increase In Institutional Ownership, Q4 Catalyst Make Venaxis Top Buy For Second Half Of 2013at Seeking Alpha(Sun, Aug 18)
- VENAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, Aug 14)
- Venaxis: The Hidden Gem With A 'Feel-Good' Investment Opportunityat Seeking Alpha(Thu, Aug 8)
- Venaxis to Present at Canaccord Genuity 33rd Annual Growth ConferencePR Newswire(Thu, Aug 8)
- VENAXIS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Aug 7)
- Venaxis: Well-Funded Ahead Of Multiple Catalysts Expected Through Year-Endat Seeking Alpha(Mon, Jul 29)
- 13 Stocks Under $10 Setting up to Spike Higherat TheStreet(Fri, Jul 26)
- 4 Health Care Stocks Under $10 to Watchat TheStreet(Fri, Jul 26)
- Venaxis' CEO Hosts Second Quarter 2013 Business Update Conference (Transcript)at Seeking Alpha(Tue, Jul 16)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6,154.96 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.77 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.15 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -0.18 |
|---|
Business Summary
Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The companys research and development activities primarily focus on a human acute appendicitis blood-based test.
View More